Loading...
In December 2006, the manufacturer of torcetrapib, a cholesterol ester transfer protein (CETP) inhibitor aimed at raising HDL levels, halted the entire development program for this drug. The decision was made on the basis of data from ILLUMINATE, a randomized trial comparing torcetrapib/atorvastatin combination therapy with atorvastatin monotherapy. The data showed increased rates of cardiovascular events and mortality in the combination-therapy group.
We now have data from a separate, previously completed, manufacturer-funded trial of torcetrapib known as ILLUSTRATE, which focused on endpoints measured by intravascular ultrasound (IVUS). The trial, conducted in patients with coronary disease, started with a 4- to 10-week run-in phase of ato…